Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$29.93 - $35.06 $8,829 - $10,342
-295 Reduced 14.53%
1,735 $58,000
Q3 2023

Nov 14, 2023

BUY
$31.89 - $39.03 $6,760 - $8,274
212 Added 11.66%
2,030 $66,000
Q2 2023

Aug 10, 2023

BUY
$30.5 - $37.4 $9,668 - $11,855
317 Added 21.12%
1,818 $63,000
Q1 2023

May 15, 2023

SELL
$30.8 - $53.92 $3,696 - $6,470
-120 Reduced 7.4%
1,501 $49,000
Q4 2022

Jun 14, 2023

BUY
$45.4 - $60.91 $5,448 - $7,309
120 Added 7.99%
1,621 $89.3 Million
Q3 2022

Jun 14, 2023

BUY
$42.06 - $55.45 $5,047 - $6,654
120 Added 7.99%
1,621 $71.8 Million
Q2 2022

Jun 20, 2023

BUY
$33.54 - $52.15 $4,024 - $6,258
120 Added 7.99%
1,621 $79,000
Q2 2022

Mar 30, 2023

BUY
$33.54 - $52.15 $6,875 - $10,690
205 Added 14.48%
1,621 $79,000
Q2 2022

Aug 11, 2022

BUY
$33.54 - $52.15 $6,875 - $10,690
205 Added 14.48%
1,621 $79,000
Q1 2022

Jun 20, 2023

SELL
$33.14 - $51.13 $2,816 - $4,346
-85 Reduced 5.66%
1,416 $68,000
Q1 2022

Mar 30, 2023

SELL
$33.14 - $51.13 $153,471 - $236,783
-4,631 Reduced 76.58%
1,416 $68,000
Q1 2022

May 12, 2022

SELL
$33.14 - $51.13 $153,471 - $236,783
-4,631 Reduced 76.58%
1,416 $69,000
Q4 2021

Jun 21, 2023

BUY
$34.09 - $43.91 $154,973 - $199,614
4,546 Added 302.86%
6,047 $257,000
Q4 2021

Mar 30, 2023

SELL
$34.09 - $43.91 $37,567 - $48,388
-1,102 Reduced 15.41%
6,047 $257,000
Q4 2021

Feb 15, 2022

SELL
$34.09 - $43.91 $37,567 - $48,388
-1,102 Reduced 15.41%
6,047 $258,000
Q3 2021

Jun 21, 2023

BUY
$25.68 - $38.61 $145,040 - $218,069
5,648 Added 376.28%
7,149 $274,000
Q2 2021

Jun 21, 2023

BUY
$25.96 - $33.44 $146,622 - $188,869
5,648 Added 376.28%
7,149 $201,000
Q2 2021

Mar 30, 2023

BUY
$25.96 - $33.44 $143,506 - $184,856
5,528 Added 341.02%
7,149 $201,000
Q2 2021

Aug 16, 2021

BUY
$25.96 - $33.44 $185,588 - $239,062
7,149 New
7,149 $202,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.